ERBB2 and breast carcinoma: When we evaluated oleuropein aglycone's metabolism-related anti-tumoral activity in SKBR3 breast cancer cells, we observed that oleuropein deglucosidation not only enables its pro-apoptotic effects but further enhances its anti-HER2 effects (Figure 8, left panel).